Case Study 1 — Opioids and Medical Inflation: How the Cost Inside a Workers' Comp Claim Got Away from the Industry

This case draws on the well-documented public history of the opioid epidemic in the United States and its intersection with workers' compensation medical costs through the 2000s and 2010s. It is grounded in the public record and in widely reported industry experience; consistent with the book's citation policy, specific magnitudes are kept qualitative — the pattern is what matters, and the pattern is not in dispute. The case illustrates the chapter's themes of statutory, no-limit medical benefits (§22.1), the long severity tail (§22.1), and why frequency control and return-to-work (§22.7) are the underwriter's real levers.

Background

Workers' compensation is, at bottom, two cash flows: indemnity (the lost wages it replaces) and medical (the treatment it pays for). For most of the twentieth century, indemnity was the larger and more worrisome share of the average claim. Over the late twentieth and early twenty-first centuries, that balance shifted: medical costs grew to become the dominant and fastest-rising component of workers' compensation losses in the United States. The reasons were many — medical inflation outpacing general inflation, more expensive imaging and surgery, an aging workforce — but one driver became its own crisis, and it is the cleanest illustration in the chapter of what "no dollar limit on medical" can mean when the treatment itself goes wrong.

Beginning in the late 1990s and accelerating through the 2000s, prescription opioids were marketed and prescribed for pain, including the musculoskeletal injuries — back strains, joint injuries, post-surgical pain — that make up a large share of workers' compensation claims. Because the WC medical benefit pays for reasonable and necessary treatment with no cap and no deductible to the worker, and because an injured worker in pain is the very person a physician is treating, opioids flowed into workers' compensation claims in enormous volume. For a time, this looked like ordinary medical cost. It was not. It was the beginning of a long-tail catastrophe inside a line that was supposed to be the high-frequency, low-severity part of an insurer's book.

The insurance issue: a no-limit medical benefit meets a treatment that prolongs the claim

The chapter's §22.1 makes the structural point: the WC medical benefit is statutory and uncapped. The insurer pays whatever the law deems reasonable and necessary, for as long as the injury requires treatment. That design is humane and is the heart of the grand bargain — an injured worker should never be bankrupted by the cost of healing. But it also means the cost of a claim is hostage to the course of treatment, and opioids changed that course in three expensive ways that every underwriter should understand:

• They lengthened the claim. A worker maintained on opioids for a musculoskeletal injury often stayed out of work longer, not shorter. Long-term opioid use is associated with delayed recovery and prolonged disability — which, recalling §22.7, drives the indemnity tail (more weeks off work) at the same time it drives the medical tail (more prescriptions, more management). The "moderate" claim that should have closed in months instead stayed open for years.
• They created secondary cost. Long-term opioid therapy carries its own complications — dependence, the need for additional drugs to manage side effects, addiction treatment, and in the worst cases overdose. Each of these became a compensable medical cost on a claim that began as a simple strain, because it flowed from the covered injury and its treatment.
• They turned frequency into severity. This is the underwriting heart of the case. A book full of ordinary, small, high-frequency back-and-joint claims — exactly the claims §22.7 says dominate a fabrication or warehousing risk — could, through this single treatment pathway, see a meaningful slice of those claims metastasize into long-tail, high-severity claims that stayed open and accruing for a decade. The benign-looking frequency book had a severity time bomb inside it that no one had priced.

A note on honesty about the numbers: the dollar magnitude of opioid-related cost in workers' compensation has been studied and reported by industry research bodies and is large, but precise figures vary by source, state, and year and are debated. What is not debated, and what matters for this chapter, is the mechanism: an uncapped medical benefit, a treatment that prolonged disability, and a long tail that turned high-frequency claims into high-severity ones.

What it shows

The opioid episode is the chapter's structure run forward in time, and it teaches four things at once:

• "No limit" is a real underwriting fact, not a slogan (§22.1). The absence of a per-claim cap means the severity tail is genuinely open-ended, and the cost is determined after you bind, by a treatment course you do not control. You price a distribution whose tail someone else is writing.
• Frequency is the leading indicator of severity (§22.7). The claims that became catastrophic started as the routine small claims that an underwriter is tempted to dismiss as noise. The shop with many small injuries was the shop most exposed to the pathway — which is exactly why §22.7 insists that frequency, not the absence of a single big claim, is the thing to watch.
• The X-mod responds, but slowly and from behind (§22.3). As these claims stayed open and developed, they fed into employers' experience and pushed mods up — but with a lag, because the mod is backward- looking and the development took years. An underwriter relying only on the current mod, without reading the open claims and their treatment status, was reading old news.
• Medical management is loss control (§22.7). The industry's eventual response was, in effect, a giant loss-control program aimed at the medical side of the claim — and it worked.

Outcome and lesson

The response was broad, public, and ultimately effective at bending the curve. State workers' compensation systems adopted drug formularies (lists restricting which drugs are reimbursable without special authorization for an injury), treatment guidelines for pain, prescription-monitoring and utilization-review programs, and a hard pivot in claims practice toward early intervention, physical therapy, and return-to-work rather than long-term pharmacological management. Insurers built pharmacy-benefit management into their claims operations specifically for WC. Over the 2010s, opioid prescribing within workers' compensation declined substantially, and the share of new claims drifting into long-term opioid use fell. The crisis did not vanish — legacy claims opened a decade earlier still carry their tail — but the new inflow was brought under control by treating the medical course of the claim as something to be actively managed, not passively paid.

The lesson for the underwriter is the chapter's deepest one, and it generalizes far beyond opioids. In a line with an uncapped medical benefit, the cost of a claim is set by what happens after the injury, which means loss control is not a discount you grant but the substance of the risk. Two underwriters can write the identical fabrication shop at the identical X-mod; the one whose insured runs early intervention, disciplined medical management, and aggressive return-to-work will see those small back strains close in weeks, while the other watches a slice of them develop into the long-tail claims that wreck a loss ratio three years later. You cannot cap the medical benefit — the statute forbids it. What you can do is select and condition for the employer who manages the claim well, credit it (§22.7), verify it at renewal, and price the one who doesn't for the tail you know is coming. The opioid story is what happens when an industry forgets that the price of a no-limit benefit is eternal vigilance over the treatment it pays for.

Discussion questions

1. The chapter (§22.1) calls workers' comp "the high-frequency, low-severity part of the book." Using the opioid case, explain how a frequency book turned into a severity problem, and why that should change how an underwriter reads a string of "small" back-injury claims.
2. The WC medical benefit is uncapped by statute and cannot be limited by the underwriter. Given that, name three things an underwriter can do at selection and at renewal to manage medical-cost risk on a claim it cannot cap. (§22.5, §22.7)
3. The X-mod rose in response to opioid-driven development, but with a lag. Explain why relying on the current X-mod alone would have understated the risk during the years the crisis was building, and what an underwriter should have read instead. (§22.3)
4. Drug formularies and treatment guidelines are, in effect, the state doing loss control on the medical side of every claim. Connect this to the chapter's point that WC is the most state-specific line (§22.1): how might two otherwise-identical employers in two different states carry different medical-cost tails purely because of their states' formulary and guideline regimes?
5. The grand bargain promises the injured worker uncapped medical care. Using the book's sixth theme (insurance serves a social function), argue why bending the opioid curve was both a loss-ratio win for insurers and a benefit to injured workers — and why those two goals were aligned, not in tension, here.